HKSE · 3839.HK
CPBIO Holding Company Limited
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
Loading market information…
OTC · MRZM · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Marizyme, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.3% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Marizyme, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:22 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$7.81+HK$0.19 (+2.43%)
CPBIO Holding Company Limited’s quoted price sits in the upper half of its reported 52-week range, 21.08% below the high.
$0.25$0.00 (0.0%)
Biomind Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.73% below the high.
$0.03-$0.00 (0.0%)
Bionoid Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.3% below the high.
$0.14-$0.04 (-22.22%)
International Stem Cell Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.07% below the high.
$0.06$0.00 (0.0%)
Unity Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.19% below the high.
$0.00+$0.00 (+12.5%)
Halberd Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.0% below the high.
$0.01-$0.00 (-7.69%)
Evofem Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
$0.01$0.00 (0.0%)
Biocure Technology Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.71% below the high.
